FFO
CCCC icon

Fortitude Family Office’s C4 Therapeutics CCCC Stock Holding History

Fortitude Family Office’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.03K Hold
435
– – ﹤0.01% 1479
2026
Q1 		$1.14K Buy
+435
New +$1.02K ﹤0.01% 1475
2025
Q3 		– Sell
-325
Closed -$465 – 2011
2025
Q2 		$465 Buy
+325
New +$473 ﹤0.01% 1849

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return
OCWP
Owl Creek Wealth Partners Denver, Colorado $342M AUM

Fortitude Family Office's CCCC Position: Q2 2026 in Review

Fortitude Family Office held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 435 shares worth $2.03K. The position accounts for ﹤0.01% of the portfolio, ranked #1479.

Fortitude Family Office first reported a position in CCCC in Q2 2025 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Fortitude Family Office held 435 shares of C4 Therapeutics worth $2.03K as of Q2 2026.
  • Fortitude Family Office left its C4 Therapeutics share count unchanged in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1479 holding.
  • Fortitude Family Office first reported a position in C4 Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 5 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.